Skyrizi
E697097
Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Skyrizi canonical | 1 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
monoclonal antibody ⓘ prescription drug ⓘ |
| actsOn | immune system ⓘ |
| administrationFrequency |
every 12 weeks for maintenance in plaque psoriasis
ⓘ
every 12 weeks for maintenance in psoriatic arthritis ⓘ every 8 weeks for maintenance in Crohn’s disease (subcutaneous phase) ⓘ |
| approvalYear | 2019 ⓘ |
| approvedFor |
adult patients with active psoriatic arthritis
ⓘ
adult patients with moderate to severe plaque psoriasis ⓘ adult patients with moderately to severely active Crohn’s disease ⓘ |
| ATCCode | L04AC18 ⓘ |
| blackBoxWarning | risk of serious infections ⓘ |
| coDevelopedBy | Boehringer Ingelheim NERFINISHED ⓘ |
| commonAdverseEffect |
fatigue
ⓘ
headache ⓘ injection site reactions ⓘ upper respiratory tract infection ⓘ |
| contraindication | hypersensitivity to risankizumab ⓘ |
| developedBy | AbbVie NERFINISHED ⓘ |
| dosingForm |
on-body injector
ⓘ
prefilled pen ⓘ prefilled syringe ⓘ |
| hasGenericName | risankizumab NERFINISHED ⓘ |
| indication |
Crohn’s disease
ⓘ
moderate to severe plaque psoriasis ⓘ moderately to severely active Crohn’s disease ⓘ psoriatic arthritis ⓘ |
| initialDosing |
intravenous induction regimen for Crohn’s disease
ⓘ
subcutaneous loading doses for plaque psoriasis ⓘ |
| legalStatus | prescription only ⓘ |
| mechanismOfAction |
binds to IL-23 p19 subunit
ⓘ
selective inhibition of IL-23 pathway ⓘ |
| pharmacologicClass | humanized IgG1 monoclonal antibody ⓘ |
| pregnancyCategory | insufficient human data ⓘ |
| reduces |
inflammatory cytokine signaling mediated by IL-23
ⓘ
intestinal inflammation in Crohn’s disease ⓘ psoriasis skin lesions ⓘ signs and symptoms of psoriatic arthritis ⓘ |
| regulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| requiresMonitoring | signs and symptoms of infection ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targets |
IL-23 p19 subunit
NERFINISHED
ⓘ
interleukin-23 ⓘ |
| therapeuticClass |
IL-23 inhibitor
ⓘ
immunosuppressant ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.